1. Home
  2. EGY vs ARVN Comparison

EGY vs ARVN Comparison

Compare EGY & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VAALCO Energy Inc.

EGY

VAALCO Energy Inc.

HOLD

Current Price

$5.20

Market Cap

569.3M

Sector

Energy

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.95

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EGY
ARVN
Founded
1985
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
569.3M
658.2M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
EGY
ARVN
Price
$5.20
$8.95
Analyst Decision
Strong Buy
Buy
Analyst Count
1
19
Target Price
$7.30
$15.05
AVG Volume (30 Days)
1.2M
858.9K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
3.75%
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
$359,272,000.00
$262,600,000.00
Revenue This Year
$8.78
N/A
Revenue Next Year
$29.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$6.06
52 Week High
$6.72
$14.22

Technical Indicators

Market Signals
Indicator
EGY
ARVN
Relative Strength Index (RSI) 32.23 37.05
Support Level $5.01 $8.72
Resistance Level $5.38 $10.18
Average True Range (ATR) 0.19 0.47
MACD -0.10 0.00
Stochastic Oscillator 6.74 28.82

Price Performance

Historical Comparison
EGY
ARVN

About EGY VAALCO Energy Inc.

VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: